| Revision as of 18:14, 16 February 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 473150225 of page 4-HO-DiPT for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Latest revision as of 10:24, 21 October 2024 edit JWBE (talk | contribs)Extended confirmed users10,126 edits removed Category:Phenols; added Category:Hydroxyarenes using HotCat |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
|
{{Use dmy dates|date=April 2023}} |
|
{{Drugbox |
|
{{Drugbox |
|
|
| Verifiedfields = changed |
|
| verifiedrevid = 399321352 |
|
|
|
| verifiedrevid = 477221993 |
|
| IUPAC_name = 3--1''H''-indol-4-ol |
|
| IUPAC_name = 3--1''H''-indol-4-ol |
|
| image = 4-HO-DIPT.SVG |
|
| image = 4-HO-DIPT.SVG |
|
| width = 140 |
|
| width = 200px |
|
| image2 = 4-HO-DiPT-3d-sticks.png |
|
| image2 = 4-HO-DiPT-3d-sticks.png |
|
|
| width2 = 200px |
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
|
| tradename = |
|
| tradename = |
| Line 14: |
Line 16: |
|
| legal_AU = |
|
| legal_AU = |
|
| legal_CA = |
|
| legal_CA = |
|
| legal_UK = |
|
| legal_DE = NpSG |
|
|
| legal_UK = Class A |
|
| legal_US = May be considered Illegal in US (Analogue of Psilocin) |
|
|
|
| legal_US = Unscheduled |
|
| legal_status = May be considered Illegal in US (Analogue of Psilocin) |
|
|
|
| legal_status = |
|
| routes_of_administration = Oral |
|
| routes_of_administration = Oral |
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!--Pharmacokinetic data--> |
|
| bioavailability = |
|
| bioavailability = |
| Line 25: |
Line 27: |
|
| elimination_half-life = 1-2 hrs |
|
| elimination_half-life = 1-2 hrs |
|
| excretion = |
|
| excretion = |
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|correct|CAS}} |
|
| CAS_number = <!-- blanked - oldvalue: 63065-90-7 --> |
|
| CAS_number = 132328-45-1 |
|
|
| index2_label = HCl |
|
|
| CAS_number2_Ref = {{cascite|correct|CAS}} |
|
|
| CAS_number2 = 63065-90-7 |
|
|
| UNII2_Ref = {{fdacite|correct|FDA}} |
|
|
| UNII2 = KE76PMQ2P3 |
|
| ATC_prefix = |
|
| ATC_prefix = |
|
| ATC_suffix = |
|
| ATC_suffix = |
|
| PubChem = |
|
| PubChem = |
|
|
| UNII_Ref = {{fdacite|changed|FDA}} |
|
|
| UNII = YG9OUS518B |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID = 10579819 |
|
| ChemSpiderID = 10579819 |
|
|
|
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
| C=16 | H=24 | N=2 | O=1 |
|
| C=16 | H=24 | N=2 | O=1 |
|
|
| smiles = CC(C)N(CCc1cc2cccc(O)c12)C(C)C |
|
| molecular_weight = 260.38 g/mol |
|
|
| smiles = CC(C)N(CCc2cnc1cccc(O)c12)C(C)C |
|
|
| InChI = 1/C16H24N2O/c1-11(2)18(12(3)4)9-8-13-10-17-14-6-5-7-15(19)16(13)14/h5-7,10-12,17,19H,8-9H2,1-4H3 |
|
|
| InChIKey = KBRYKXCBGISXQV-UHFFFAOYAT |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C16H24N2O/c1-11(2)18(12(3)4)9-8-13-10-17-14-6-5-7-15(19)16(13)14/h5-7,10-12,17,19H,8-9H2,1-4H3 |
|
| StdInChI = 1S/C16H24N2O/c1-11(2)18(12(3)4)9-8-13-10-17-14-6-5-7-15(19)16(13)14/h5-7,10-12,17,19H,8-9H2,1-4H3 |
| Line 48: |
Line 52: |
|
| melting_high = |
|
| melting_high = |
|
}} |
|
}} |
|
|
] |
|
|
'''4-Hydroxy-N,N-diisopropyltryptamine''' ('''4-HO-DiPT''' or '''Iprocin''') is a synthetic ]. It is a higher ] of ], ], and is a positional isomer of ] and has a ] molecular sub-structure. |
|
|
|
|
|
==Dosage== |
|
|
4-HO-DiPT is orally active at around 3 mg and above, and its effects last for 2–3 hours.<ref name="Erowid.org 4-HO-DiPT Dosage Vault">{{Cite web|url=https://www.erowid.org/chemicals/4_ho_dipt/4_ho_dipt_dose.shtml|title=Erowid 4-HO-DiPT Vault : Dosage|website=www.erowid.org|accessdate=8 April 2023}}</ref> Higher doses such as those above 30 mgs can increase the duration of the effects significantly. |
|
|
|
|
|
==Effects== |
|
|
The effects of 4-HO-DiPT are broadly comparable to those of other serotonergic psychedelics such as ] and ], but they are distinguished by their relative brevity. ] "doubt that there is another psychedelic drug, anywhere, that can match this one for speed, for intensity, for brevity, and sensitivity to dose, at least one that is active orally." An idiosyncratic effect of the drug, also noted by Shulgin, is its tendency to induce tremors.<ref>{{CiteTiHKAL}}</ref><ref>{{cite web | title = 4-Hydroxy-DIPT | url = https://www.erowid.org/chemicals/4_ho_dipt/4_ho_dipt.shtml | work = Erowid }}</ref><ref>{{cite web | title = Tihkal 4-HO-DIPT entry| url = https://www.erowid.org/library/books_online/tihkal/tihkal17.shtml }}</ref> |
|
|
|
|
|
Some users have reported a minor audio distortion with lower dosages. Higher dosages increase the polarity of the distortion. It is defined as being slightly lower in pitch and creating several different effects, such as pitch bend, volume distortion, and rate distortion. As with most ] psychedelics, music can become more dissonant and less harmonious. Users have also reported a visual distortion widely comparable to the hallucinogen ]. |
|
|
|
|
|
==Pharmacology== |
|
|
|
|
|
===Pharmacodynamics=== |
|
|
{| class="wikitable" |
|
|
|- |
|
|
! Binding Sites |
|
|
! Binding Affinity Ki (μM) |
|
|
! Action <ref name="pmid27216487">{{cite journal | vauthors = Rickli A, Moning OD, Hoener MC, Liechti ME | title = Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens | journal = European Neuropsychopharmacology | volume = 26 | issue = 8 | pages = 1327–37 | date = August 2016 | pmid = 27216487 | doi = 10.1016/j.euroneuro.2016.05.001 | s2cid = 6685927 | url = http://edoc.unibas.ch/53326/1/20170117174852_587e4af45b658.pdf }}</ref> |
|
|
|- |
|
|
| ] |
|
|
| 5.7 |
|
|
| ??? |
|
|
|- |
|
|
| ] |
|
|
| 0.728 |
|
|
| ] |
|
|
|- |
|
|
| ] |
|
|
| 2.8 |
|
|
| ??? |
|
|
|- |
|
|
| ] |
|
|
| >25 |
|
|
| ??? |
|
|
|- |
|
|
| ] |
|
|
| >25 |
|
|
| ??? |
|
|
|- |
|
|
| ] |
|
|
| >25 |
|
|
| ??? |
|
|
|- |
|
|
| ] |
|
|
| >12 |
|
|
| ??? |
|
|
|- |
|
|
| ] |
|
|
| 15 |
|
|
| ??? |
|
|
|- |
|
|
| ] |
|
|
| >15 |
|
|
| ??? |
|
|
|- |
|
|
| ] |
|
|
| 9.8 |
|
|
| ??? |
|
|
|- |
|
|
| ] |
|
|
| 1.8 |
|
|
| ] |
|
|
|- |
|
|
| ] |
|
|
| >26 |
|
|
| ] |
|
|
|- |
|
|
| ] |
|
|
| 11 |
|
|
| ] |
|
|
|} |
|
|
|
|
|
==Clinical trials== |
|
|
], a ] to 4-HO-DiPT, has entered double blind, randomized, placebo controlled, phase 1 clinical trials in healthy volunteers at the ] in Australia for the treatment of ] and ]. <ref>{{cite press release | url=https://www.globenewswire.com/en/news-release/2022/07/21/2483532/0/en/Field-Trip-Announces-First-Dosings-in-Phase-I-Clinical-Study-of-FT-104.html | title=Field Trip Announces First Dosings in Phase I Clinical Study of FT-104 | date=21 July 2022 }}</ref><ref>{{cite web | url=https://psychedelicspotlight.com/an-inside-look-into-field-trips-next-generation-psychedelic-ft-104/ | title=An Inside Look into Field Trip's Next-Generation Psychedelic, FT-104 | date=11 August 2022 }}</ref><ref>{{Cite web|url=https://patentscope.wipo.int/search/en/detail.jsf;?docId=US346005716|title=WIPO - Search International and National Patent Collections|website=patentscope.wipo.int|accessdate=8 April 2023}}</ref> |
|
|
]]{{clear-left}} |
|
|
{{commonscat}} |
|
|
|
|
|
==Legal status== |
|
|
===Finland=== |
|
|
Scheduled in government decree on psychoactive substances banned from the consumer market.<ref>{{Cite web|url=https://www.finlex.fi/fi/laki/alkup/2014/20141130|title=FINLEX ® - Säädökset alkuperäisinä: Valtioneuvoston asetus kuluttajamarkkinoilta… 1130/2014|website=www.finlex.fi|accessdate=8 April 2023}}</ref> |
|
|
|
|
|
===Germany=== |
|
|
Scheduled in New Psychoactive Substances Act (]). Use of covered substances is permitted only for industrial and scientific purposes. |
|
|
|
|
|
===Sweden=== |
|
|
] health ministry ] classified 4-HO-DiPT as "health hazard" under the act ] (translated ''Act on the Prohibition of Certain Goods Dangerous to Health'') as of Mar 1, 2005, in their regulation '''SFS 2005:26''' listed as '''4-hydroxi-N,N-diisopropyltryptamin (4-HO-DIPT)''', making it illegal to sell or possess.<ref>{{cite web | title = Svensk författningssamling | trans-title = Swedish Code of Statutes | language = Swedish | url = http://www.notisum.se/rnp/sls/sfs/20050026.pdf | access-date = 25 September 2013 | archive-date = 29 September 2013 | archive-url = https://web.archive.org/web/20130929063138/http://www.notisum.se/rnp/sls/sfs/20050026.pdf | url-status = dead }}</ref> |
|
|
|
|
|
===United States=== |
|
|
4-HO-DiPT is not scheduled at the federal level in the ],<ref name="PART 1308 — SCHEDULES OF CONTROLLED SUBSTANCES - 1308.11 Schedule I">{{Cite web |url=http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm |title=21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I. |access-date=2014-12-17 |archive-date=2009-08-27 |archive-url=https://web.archive.org/web/20090827043725/http://www.deadiversion.usdoj.gov/21cfr/cfr/1308/1308_11.htm |url-status=dead }}</ref> but it is possible that it could be considered an analog of ], in which case purchase, sale, or possession could be prosecuted under the ]. |
|
|
|
|
|
====Florida==== |
|
|
"4-Hydroxy-N,N-diisopropyltryptamine" is a Schedule I ] in the state of ] making it illegal to buy, sell, or possess in Florida.<ref name="Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL">{{Cite web|url=http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html|title=Statutes & Constitution :View Statutes : Online Sunshine|website=leg.state.fl.us|accessdate=8 April 2023}}</ref> |
|
|
|
|
|
== References == |
|
|
{{reflist}} |
|
|
|
|
|
== External links == |
|
|
* |
|
|
* |
|
|
|
|
|
{{Hallucinogens}} |
|
|
{{Tryptamines}} |
|
|
|
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |